Loading clinical trials...
Loading clinical trials...
A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain
Conditions
Interventions
75 mg linzagolix tablet
200 mg linzagolix tablet
+4 more
Locations
47
United States
Choice Research, LLC/ ID # 609
Dothan, Alabama, United States
Universal Axon - Homestead, LLC/ ID # 620
Homestead, Florida, United States
Stedman Clinical Trials/ ID # 612
Tampa, Florida, United States
Advanced Specialty Research/ ID # 610
Nampa, Idaho, United States
Women's & Family Care, LLC dba GTC Research/ ID # 608
Shawnee Mission, Kansas, United States
Southern Clinical Research / ID # 611
Metairie, Louisiana, United States
Start Date
March 5, 2020
Primary Completion Date
September 15, 2022
Completion Date
December 15, 2022
Last Updated
April 2, 2025
NCT07472842
NCT07471373
NCT05951452
NCT06611501
NCT07100782
NCT06974773
Lead Sponsor
Kissei Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions